COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion
- PMID: 32474220
- PMCID: PMC7251406
- DOI: 10.1016/j.jns.2020.116941
COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion
Abstract
- •
We demonstrated the first patient with COVID-19 developing an isolated SCC lesion on brain MRI, suggestive of mild encephalitis/encephalopathy with a reversible splenial lesion (MERS).
- •
MERS can be considered as a differential diagnosis for neurological symptoms of COVID-19, especially when patients develop transient cerebellar ataxia or disorientation.
Keywords: COVID-19; Clinically mild encephalitis; Encephalitis; Encephalopathy with a reversible splenial; Lesion; MERS.
Conflict of interest statement
Declaration of Competing Interest None.
Figures

References
-
- Tada H., Takanashi J., Barkovich A.J. Clinically mild encephalitis/encephalopathy with a reversible splenial lesion. Neurology. 2004;63(10):1854–1858. - PubMed
-
- Doherty M.J., Jayadev S., Watson N.F. Clinical implications of splenium magnetic resonance imaging signal changes. Arch. Neurol. 2005 Mar;62(3):433–437. - PubMed
-
- Imai N., Yagi N., Konishi T., Serizawa M., Kobari M. Legionnaires’ disease with hypoperfusion in the cerebellum and frontal lobe on single photon emission computed tomography. Intern. Med. 2008;47(13):1263–1266. - PubMed
-
- Hoshino A., Saitoh M., Oka A. Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes. Brain Dev. 2012;34(5):337–343. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials